VEGFR-2/DHFR-IN-1 (compound 8b) is a chemical inhibitor of VEGFR-2 and DHFR, with IC50 values of 0.384 μM and 7.881 μM, respectively. It possesses effective antibacterial activity against pathogens including Escherichia coli, Streptococcus faecalis, Salmonella enterica, MSSA, and MRSA, with MIC values ranging from 8 to 16 μg/mL. Additionally, it exhibits potent cytotoxicity against cancer cell lines C26, HepG2, and MCF7, with IC50 values between 2.97 and 7.12 μM, making it a valuable tool for cancer research [1].

VEGFR-2/DHFR-IN-1, at concentrations ranging from 2-1024 μg/mL over 18-72 hours, demonstrates significant antimicrobial activity, as evidenced by minimum inhibitory concentration (MIC) values against a variety of pathogens: 16 μg/mL for Escherichia coli, 64 μg/mL for Pseudomonas aeruginosa, 16 μg/mL for Streptococcus faecalis, 16 μg/mL for Salmonella enterica, 8 μg/mL for MSSA, 16 μg/mL for MRSA, 64 μg/mL for Candida albicans, and 256 μg/mL for Aspergillus niger. Additionally, at 0.5-100 μM for 48 hours, it exhibits potent anticancer effects. Its inhibitory action on DHFR and VEGFR-2, identified through concentrations of 0-100 μM over 30 minutes, shows IC50s of 7.881 μM and 0.384 μM, respectively. Furthermore, cell cytotoxicity assays on C26, HepG2, MCF7, and H69PR cell lines, using concentrations between 0.5 and 100 μM over 48 hours, reveal VEGFR-2/DHFR-IN-1's anticancer capabilities, with IC50s of 2.97 μM for C26, 7.12 μM for HepG2, 3.58 μM for MCF7, and 12.79 μM for H69PR cells.